We can't find the internet
Attempting to reconnect
15235.1 PFLS-LS
HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci
Résumé
HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci
Textes supplémentaires
Abstract
A new and highly innovative treatment will be realized by a novel and patentable small molecule|combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic|staphylococci. The consortium integrates a screening platform, biophysical characterization of small|molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models,|to develop initial HIT compounds into preclinical candidates
Participants
Marc Gitzinger
Wirtschaftspartner
BioVersys AG Marc Gitzinger Hochbergerstrasse 60c 4057 Basel BS CH
Rainer Riedl
Kontaktperson
rainer.riedl@zhaw.ch
ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2013-07-31
- Date de fin
- 2015-07-31
- Coûts totaux approuvés
- CHF 971582.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%